FCF Pharmaceutical Market Study – 2021 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Pharmaceutical Market Study – 2021”.

Based on available data from European pharmaceutical providers, the FCF Pharmaceutical Market Study is a detailed and comprehensive analysis of the pharmaceutical sector and especially addresses the European small- / midcap market segment.

Key findings of the FCF Pharmaceutical Market Study (December 2021):
  • Revenue is expected to increase by +6.7% from ’20 to ’21
  • EBITDA is expected to increase by +13.7% from ’20 to ’2
  • EBIT is expected to increase by +14.5% from ’20 to ’21
  • EV / EBITDA valuation multiple increased from 12.4x in ’20 to 15.9x LTM
  • Net leverage slightly stayed at 1.6x in ’20 and LTM
  • Interest cover ratio decreased from 58.1x in ’20 to 51.4x LTM
  • The number of Private Equity (PE) deals increased from 42 in ’19 to 53 in ’20 and M&A deal activity increased from 35 in ’19 to 43 in ‘20
Share on linkedin
Share